Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
GIPR activation enhances adipose tissue lipid buffering, improves beta-cell function, and may amplify central anorectic signaling
2008 Jul-Aug Anna E Kirkland, Gabrielle L Sarlo, Kathleen F Holton
Nestle Nutr Inst Workshop Ser
People most at risk include those who: have type 2 diabetes use insulin or sulfonylurea miss meals have recently increased their dose Symptoms of low blood sugar can include: shaking sweating dizziness hunger headache confusion feeling faint If hypoglycaemia is suspected, it should be treated immediately with fast-acting carbohydrates, such as glucose tablets or a sugary drink
Published research has reported the following reference ranges: Preclinical (rodent) models: doses in the range of 0.13 nmol/kg administered at periodic intervals to evaluate pharmacokinetics, receptor activation, and metabolic signaling responses Early-phase clinical investigations: escalating dose protocols beginning at sub-milligram weekly doses, as reported in Phase 1 and Phase 2 trial literature (Coskun et al., 2022) In vitro systems: receptor binding and activation studies conducted at nanomolar concentrations to evaluate GLP-1R, GIPR, and GCGR engagement These values are model- and protocol-specific and do not translate directly to human use
Oral therapies can be administered to patients of all age groups, enhancing their widespread availability
US$ 20.21
US$ 28.53
US$ 21.04
US$ 28.16
US$ 20.69
US$ 26.86
